Hal Barron, GlaxoSmithKline president of R&D (Endpoints file photo)
June 16, 2020 07:07 AM EDTUpdated 07:28 AM
Deals

Bil­lions on the ta­ble, GSK’s Hal Bar­ron antes $120M cash to part­ner with a spe­cial­ist in syn­thet­ic lethal­i­ty

John Carroll

Editor & Founder

GSK R&D chief Hal Bar­ron has turned to an­oth­er Bay Area biotech for his lat­est on­col­o­gy drug de­vel­op­ment pact, which could to­tal bil­lions for a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

A service from the Financial Times